Immunology and Microbiology
Asthma
100%
Severe Asthma
58%
Rhinovirus
45%
Asthma Exacerbation
39%
Airway
27%
Eosinophil
19%
Interferon Type I
19%
Biological Product
18%
Benralizumab
16%
Viral Disease
14%
Virus
13%
Cytokine
9%
Interleukin 5
9%
Immune Response
9%
Prevalence
9%
Allergic Inflammation
8%
Normal Human
7%
Respiratory Virus
7%
Sensitization
7%
Immunoglobulin E
6%
Interleukin 15
6%
Allergic Asthma
6%
Chemokine
6%
Dupilumab
5%
Immunology
5%
Interleukin 13
5%
CCL17
5%
Macrophage
5%
Allergen
5%
T Cell
5%
Medicine and Dentistry
Asthma
66%
Severe Asthma
44%
Eosinophilic
23%
Diseases
22%
Eosinophil
20%
Biological Product
13%
Benralizumab
12%
Primary Health Care
12%
Rhinovirus Infection
8%
COVID-19
8%
Mepolizumab
7%
Biological Therapy
7%
Patient Compliance
6%
Biological Marker
6%
Nasal Polyp
6%
Reslizumab
5%
Eosinophilic Granulomatosis with Polyangiitis
5%
Respiratory Tract Allergy
5%
Patient with Asthma
5%
Quality of Life
5%
Patient Referral
5%
Clinical Trial
5%
Adrenal Insufficiency
5%
Respiratory Tract Inflammation
5%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
55%
Diseases
27%
Benralizumab
19%
Mepolizumab
10%
Inflammation
9%
Respiratory Tract Disease
7%
Virus Infection
6%
Biological Product
5%
